Human T-lymphotropic virus type II and neurological disease

dc.creatorAraújo, Abelardo
dc.creatorHall, William W.
dc.date2019-06-21T12:19:53Z
dc.date2019-06-21T12:19:53Z
dc.date2004
dc.date.accessioned2023-09-26T23:57:22Z
dc.date.available2023-09-26T23:57:22Z
dc.identifierARAUJO, Abelardo; HALL, William W. Human T-lymphotropic virus type II and neurological disease. Annals of Neurology, v. 56, n. 1, p. 10-19, July 2004.
dc.identifier0364-5134
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/33614
dc.identifier10.1002/ana.20126
dc.identifier1531-8249
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8895976
dc.descriptionHuman T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II) are closely related retroviruses with similar bio-logical properties and common modes of transmission. HTLV-I infection is endemic in well-defined geographic regions,and it is estimated that some 20 million individuals are infected worldwide. Although most infected individuals areasymptomatic carriers, some 2 to 5% will develop a chronic encephalomyelopathy, HTLV-I–associated myelopathy/tropical spastic paraparesis (HAM/TSP). In contrast with HTLV-I, the role of HTLV-II in the development of neuro-logical disorders is much less clear. HTLV-II is endemic in many native Amerindian groups and epidemic in injectingdrug users (IDUs) worldwide. To evaluate the role of HTLV-II in neurological disease, we have critically reviewed allreported cases of HTLV-II–associated disorders. This has confirmed that although rare infection is associated with adisorder clinically similar or identical to HAM/TSP. However, most reports that have attributed infection to a range ofother neurological disorders are difficult to evaluate in that in many cases either the association appears to be fortuitousor the presentations were confounded by a background of concomitant human immunodeficiency virus–1 infectionand/or active IDU. In view of the many HTLV-II–infected individuals in urban areas of North America and Europe,neurologists should be aware of the potential clinical consequences of this infection.
dc.description2020-06-21
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsopen access
dc.subjectHTLV-I
dc.subjectHTLV-II
dc.subjectNeurological disease
dc.titleHuman T-lymphotropic virus type II and neurological disease
dc.typeArticle


Este ítem pertenece a la siguiente institución